| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Integrative Physiology |
From the University Hospital Aachen, Department of Medicine, Division of Cardiology, Pulmonary and Vascular Diseases (T.R., C.D., U.H.-C., M.K.), Aachen; and the Department of Cardiovascular Physiology (U.F., J.S.), Heinrich-Heine-University Düsseldorf, Germany.
Correspondence Tienush Rassaf, MD, University Hospital Aachen, Department of Medicine, Division of Cardiology, Pulmonary and Vascular Diseases, Pauwelsstr. 30, D-52074 Aachen, Germany. E-mail trassaf{at}ukaachen.de
| Abstract |
|---|
|
|
|---|
Key Words: nitrite hypoxia myoglobin cardiac function
| Introduction |
|---|
|
|
|---|
| Materials and Methods |
|---|
|
|
|---|
NO Analysis of Cardiac Tissue
Tissue nitroso species (the sum of S-nitrosothiols and the mercury-stable NO-adducts N-nitrosamines, iron-nitrosyles11) and nitrite were determined applying group-specific reductive denitrosation by triiodine with subsequent detection of the NO liberated by gas-phase-chemiluminescence.11,12 Nitrate was quantified after enzymatic reduction to nitrite by nitrate reductase using flow-injection analysis based on the Griess reaction.13,14 NO-heme was determined by parallel injection of replicate aliquots of tissue homogenates into a 0.05 mol/L ferricyanide solution to achieve 1-electron oxidation and quantify the liberated NO using gas-phase-chemiluminescence.10
Animals and Langendorff Heart Perfusion
All experiments were approved by the local ethic committee. NO synthase activity was blocked in all animals by pretreatment with L-N(5)-(1-iminoethyl)-ornithine (L-NIO).15 Preparation and perfusion of murine hearts of myo/7 and wt animals were performed essentially as described.16 Until excision of the heart, animals received standard rodent chow. For NMR measurements, hearts were placed inside a 10-mm NMR tube, immersed in perfusion buffer (containing in mmol/L: NaCl 116, KCl 4.6, MgSO4 1.1, NaHCO3 24.9, CaCl2 2.5, KH2PO4 1.2, glucose 8.3, and EDTA 0.5), and transferred into a heated (37°C) 10-mm 1H/31P dual probe inside the spectrometer. Perfusion pressure, coronary flow, and left ventricular developed pressure (LVDP) were measured continuously. Signals were recorded with a sampling rate of 1000 Hz using a PC with dedicated software (Chart, AD Instruments). Arterial and venous pO2 were measured simultaneously with implantable oxygen microsensors based on 140-µm optical silica fiber (Presens) as previously described.17 All hearts were initially perfused at constant coronary pressure with Krebs-Henseleit buffer equilibrated with 95% O2/5% CO2. After heart function had stabilized inside the magnet, cardiac pacing (500 bpm) was initiated and continued throughout. Left ventricular end-diastolic pressure was set to 5 mm Hg. Thirty minutes after the onset of cardiac pacing, coronary perfusion was fixed to the steady flow at which the hearts had stabilized. After the switch to constant flow, baseline data were recorded. Perfusion was then turned to buffer gassed at 50% O2/45% N2/5% CO2 (Figure 1) to induce partial deoxygenation of Mb and a normoxic buffer (95% O2/ 5% CO2) as control, respectively. Subsequently, solutions with increasing concentrations of nitrite (0.1; 1; 10; 100 µmol/L) were infused stepwise, and in each section of the protocol hemodynamic data as well as NMR spectra were acquired.
|
31P NMR Spectroscopy
Spectra were recorded at a Bruker DRX 400 WB NMR spectrometer, operating at frequencies of 400 MHz for 1H and 161.97 MHz for 31P. Shimming was done on the free induction decay of the water signal. A line width at half height of 15 Hz could be routinely obtained. Transients (n=240) were accumulated with a 75-degree flip angle, a repetition time of 1 second, a spectral width of 5682 Hz, a data size of 4K, zero filling to 8K, and exponential weighting resulting in a 10-Hz line broadening (4 minutes of signal accumulation). Chemical shifts were referenced to the phosphocreatine (PCr) resonance at 2.52 ppm. After baseline correction relative peak areas were obtained by integration and converted to concentrations as described before.16 Calculated values for the free energy of adenosine-triphosphate (ATP) hydrolysis (
GATP) were derived from established relations.
| Results |
|---|
|
|
|---|
To characterize the total amount of NO formed by reaction with Mb, consecutive reactions of NO have to be considered. In analogy to what has been reported for Hb, NO released from Mb can be captured by the remaining deoxygenated Mb (deoxyMb; MbFeII) as nitrosylated Mb (nitrosyl-Mb; MbFeII-NO), which therefore can serve as an index of NO-formation.9 Using the same gas-phase-chemiluminescence approach described above, but adding ferricyanide to liberate the Mb-bound NO, we found a substantial Mb-mediated formation of NO at physiologically relevant cytosolic levels of pO2 and nitrite (Figure 2A and 2B). The release of NO into the gas phase increased with the deoxygenation level of Mb and the concentration of nitrite.
|
We next analyzed the release of NO using murine myocardial tissue homogenates (Figure 2C through 2E). The basal rate of NO formation from deoxygenated tissue homogenates in the presence of 100 µmol/L nitrite was 2.5±0.3 nmol/g/s. In comparison, in homogenates from hearts of Mb-deficient (myo/) mice the formation of NO was decreased by 60% as compared with wt controls (Figure 2E). Addition of Mb (200 µmol/L final concentration) to myo/ samples increased the formation of NO to levels of wt mice (Figure 2E). In contrast, inhibition of potential alternative nitrite-dependent NO producers,18,19 such as xanthine-oxidoreductase and the flavin-adenine dinucleotide-(FAD)-site by allopurinol and diphenyliodonium, respectively, did not reduce NO release (Figure 2D). Similarly, inhibition of the electron-transfer from ubiquinol to the bc1-complex in the mitochondrial respiratory chain by myxothiazol did not significantly reduce the formation of NO (Figure 2C).
The transport of intracoronarily applied nitrite into the myocardium has not been studied so far. To define the amounts of nitrite needed to increase endogenous levels, in a separate series of experiments we analyzed myocardial tissue content of nitrite. To differentiate between endogenous nitrite formation and the exogenously applied nitrite, NOS activity was inhibited with L-NIO15 (5 times every 30 minutes before excision of hearts). Isolated perfused mouse hearts were then subjected to mild hypoxia (50% buffer O2) which increases the fraction of deoxyMb to 50% and is associated with a cellular Po2 of less than 4 mm Hg.20 This was followed by replenishment of the nitrite pool during perfusion with increasing nitrite concentrations (0.1, 1, 10, 100 µmol/L). Baseline cardiac nitrite levels were determined to be 2.96±0.42 µmol/L, which were significantly reduced to 1.14±0.06 µmol/L by application of L-NIO (Figure 3A; n=4, P<0.05). Perfusion with buffer containing 0.1 µmol/L and 1 µmol/L nitrite did not restore the initial cardiac nitrite levels (1.15±0.13 µmol/L for 0.1 µmol/L nitrite, P=n.s., and 1.59±0.36 µmol/L for 1 µmol/L nitrite, P=n.s.). Replenishment of the depleted tissue nitrite levels was only achieved by perfusion with concentrations
10 µmol/L nitrite (Figure 3A). Buffer containing 10 µmol/L nitrite led to cardiac nitrite levels of 2.54±0.75 µmol/L, being close to basal values, whereas 100 µmol/L nitrite increased tissue levels up to 2.5-fold above basal. Additional analysis of cardiac tissue NO content after nitrite application during hypoxia revealed a significant intracellular increase in nitroso-species and NO-heme products only at the level of 10 and 100 µmol/L nitrite, respectively (Figure 3A). No increase in NO-heme and nitroso-species was seen in myo/ mice (Figure 3B).
|
Having defined the changes in myocardial tissue nitrite levels we studied the functional consequences of the Mb-mediated NO formation from nitrite (for the full protocol see Figure 1). While stepwise increasing extracellular nitrite concentrations (0.1, 1, 10, 100 µmol/L), hemodynamic analysis combined with 31P NMR spectroscopy was performed in hearts from wt mice with myo/ mice serving as appropriate controls. No changes were observed in both groups during perfusion with 0.1 and 1 µmol/L nitrite. However, at extracellular concentrations
10 µmol/L nitrite dose-dependently increased myocardial inorganic phosphate (Pi) and decreased phosphocreatine (PCr) levels in wt hearts (Figure 4), thereby reducing the free energy of ATP hydrolysis (
GATP). The impairment of the energy status was accompanied by a drop in left ventricular developed pressure and an increase of the coronary venous pO2 in wt mice. Because hearts were perfused in the constant flow mode, an increase in coronary venous pO2 reflects a reduced myocardial oxygen extraction and consumption (Figure 5). Under the same conditions no changes in energetic or functional parameters were observed in hearts of myo/ mice (Figures 4 and 5
) indicating the observed differences to be specific for deoxyMb. This conclusion is further supported by experiments in which perfusion of wt and myo/ hearts with normoxic medium (equilibration with 95% O2) and 100 µmol/L nitrite did not alter cardiac contractility (LVDP: 104±11 versus 103±13 mm Hg for WT and 102±12 versus 104±11 mm Hg for myo/), oxygen consumption (MVO2: 12±1 versus 12±1 µmol/min/g for WT and 12±1 versus 12±1 µmol/min/g for myo/), and cardiac high energy phosphates (
GATP: 61±0.3 versus 61±0.3 kJ/mol for WT and 61±0.2 versus 61±0.2 kJ/mol for myo/).
|
|
| Discussion |
|---|
|
|
|---|
It is well known that cardiac contractile function and energy metabolism are actively downregulated, when coronary blood supply is critically reduced and this "perfusion-contraction matching" is a unique feature of the heart.22 On acute coronary artery inflow reduction, contractile function of the ischemic region is rapidly decreased and is associated with a decrease in oxygen consumption. This dampens the fall in high energy phosphates and over time even can restore myocardial energy balance. The mechanisms underlying this adaptive response, termed short-term hibernation, remained largely unclear until now. On nitrite infusion we observe a scenario which strongly resembles the characteristics described for acute hibernation: a decrease in PCr, a concomitant increase in Pi, and a reduction of the available driving force for all energy-consuming processes (
GATP). Furthermore, we provide evidence for a reduction of ATP utilization (decrease in left ventricular developed pressure) and ATP synthesis (decrease in myocardial oxygen consumption) during nitrite infusion. Obviously, a new steady state for ATP is reached and ATP levels are maintained at lower steady state levels of PCr. Therefore, the pO2-dependent nonenzymatic formation of NO by reaction of Mb with nitrite may represent an important causal factor of short-term hibernation. Although the presented experiments were performed under hypoxic perfusion conditions which cause Mb to be deoxygenated by about 50%, low-flow ischemia certainly can further lower tissue pO2, thereby further augmenting the ability of deoxymyglobin to form NO from nitrite.23 It is noteworthy that Martin et al24 recently provided evidence for a NO synthaseindependent NO formation during myocardial ischemia, which can be easily explained on the basis of the present work.
Published experimental studies support our findings that under hypoxic conditions myoglobin may react with nitrite to form NO,25 and that this reaction may play a crucial role in the regulation of physiological functions.26 Similar to the present work, Shiva et al have most recently demonstrated that in isolated cardiomyocytes the nitrite reductase activity of deoxymyoglobin releases NO in proximity to mitochondria and regulates respiration through cytochrome c oxidase.27 Furthermore, different groups have shown that the application of low doses of nitrite prevents ischemia/reperfusion-injury in the Langendorff heart model18 as well as in the liver and heart of mice.28 The xanthine-oxidoreductase dependent reduction of nitrite to NO18 and a deoxyhemoglobin- and myoglobin-mediated nitrite reduction to NO27,28 have been proposed as potential mechanisms, but we (Figure 2C and 2D) and others27 were not able to show a significant role for xanthine-oxidoreductase in reducing nitrite.
Our data may be criticized that rather high extracellular concentrations of nitrite (10 to 100 µmol/L) were required to elicit the biological response. However, it is the intracellular concentration of nitrite which is of critical importance for the reaction with deoxyMb. Pretreatment of animals with the NOS inhibitor NIO decreased cytosolic nitrite by approximately 70%, and perfusion with concentrations
10 µmol/L nitrite was required to replenish the myocytic levels to the range of untreated controls. Obviously, comparatively high extracellular nitrite concentrations have to be applied under our experimental conditions to mimic the in vivo conditions with unrestricted activity of NOS and unlimited availability of its substrate arginine which was deliberately not supplemented with the perfusion buffer. Together our data suggest that the effect of nitrite on cardiac function occurred at physiological cytosolic nitrite concentrations.
NO formation by deoxyMb may not only be relevant for the heart, but it also could contribute to hypoxic vasodilation described for the human circulation.5 As already pointed out above, the total body amounts of Hb and Mb are similar so that the ability of both proteins to act as nitrite-reductase might have been involved in the vasodilation of the exercising muscle previously reported. Using 1H NMR spectroscopy the fraction of deoxyMb in skeletal muscle of healthy humans was found to be 9%.29 On exercise (50 to 60% of maximum work rate) the deoxyMb signal increases to about 50%, corresponding to an intracellular pO2 lower than 5 mm Hg.30 This is similar to values obtained in the present study with hypoxic perfusion of the heart. Using quadriceps maximum isometric voluntary torque and measuring PCr and deoxyMb by interleaved 1H and 31P NMR spectroscopy, the fraction of deoxyMb was found to increase up to 70%, whereas PCr reversibly decreased to 20% of control.31 Given this significant deoxygenation of Mb in human exercising muscle, this most likely has profoundly increased the Mb-mediated formation of NO (Figure 2). Because of the low diffusion distances between Mb and mitochondria, this NO may be critically involved in the observed inhibition of oxidative phosphorylation, which is known to be extremely NO sensitive.32 This mechanism may therefore play an important role in limiting muscle oxygen consumption and thus the exercise capacity of skeletal muscle.
In summary this study describes a novel homeostatic mechanism by which a mismatch between oxygen supply and demand is translated into the fractional increase of deoxyMb exhibiting enhanced nitrite reductase activity. DeoxyMb may act as an important oxygen sensor through which NO can regulate muscle energetics and function. This appears to be functionally important in the infarcted heart, during acute myocardial hibernation, and intense muscle exercise.
| Acknowledgments |
|---|
This work was supported by grants from the DFG: RA 969/4-1 (to T.R.); SFB 612 (to U.F. and J.S.); and GRK 1089 project 3 (to T.R., C.D., M.K.).
Disclosures
None.
| Footnotes |
|---|
Original received January 19, 2007; resubmission received March 21, 2007; revised resubmission received April 23, 2007; accepted April 30, 2007.
| References |
|---|
|
|
|---|
2. Wittenberg JB, Wittenberg BA. Myoglobin function reassessed. J Exp Biol. 2006; 206: 20112020.
3. Brunori M. Nitric oxide moves myoglobin centre stage. Trends Biochem Sci. 2001; 26: 209210.[CrossRef][Medline] [Order article via Infotrieve]
4. Flögel U, Gödecke A, Klotz LO, Schrader J. Role of myoglobin in the antioxidant defense of the heart. FASEB J. 2004; 18: 11561158.
5. Cosby K, Partovi KS, Crawford JH, Patel RP, Reiter CD, Martyr S, Yang BK, Waclawiw MA, Zalos G, Xu X, Huang KT, Shields H, Kim-Shapiro DB, Schechter AN, Cannon III RO, Gladwin MT. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med. 2003; 9: 14981505.[CrossRef][Medline] [Order article via Infotrieve]
6. Flögel U, Merx MW, Gödecke A, Decking UKM, Schrader J. Myoglobin: a scavenger of biocative NO. Proc Natl Acad Sci U S A. 2001; 98: 735740.
7. Gödecke A, Flögel U, Zanger K, Ding Z, Kirchenhain J, Decking UK. Disruption of myoglobin in mice induces multiple compensatory mechanisms. Proc Natl Acad Sci U S A. 1999; 96: 1049510500.
8. Gladwin MT, Schechter AN, Kim-Shapiro DB, Patel RP, Hogg N, Shiva S, Cannon RO, III, Kelm M, Wink DA, Espey MG, Oldfield EH, Pluta RM, Freeman BA, Lancaster JR, Jr., Feelisch M, Lundberg JO. The emerging biology of the nitrite anion. Nat Chem Biol. 2005; 1: 308314.[CrossRef][Medline] [Order article via Infotrieve]
9. Nakamura M, Nakamura S. conversion of metmyoglobin to NO myoglobin in the presence of nitrite and reductants. Biochim Biophys Acta. 1996; 1289: 329335.[Medline] [Order article via Infotrieve]
10. Bryan NS, Rassaf T, Maloney RE, Rodriguez CM, Saijo F, Rodriguez JR, Feelisch M. Cellular targets and mechanisms of nitros(yl)ation: An insight into their nature and kinetics in vivo. Proc Natl Acad Sci U S A. 2004; 101: 43084313.
11. Feelisch M, Rassaf T, Mnaimneh S, Singh N, Bryan NS, Jourdheuil D, Kelm M. Concomitant S-, N-, and heme-nitros(yl)ation in biological tissues and fluids: implications for the fate of NO in vivo. FASEB J. 2002; 16: 17751785.
12. Rassaf T, Bryan NS, Maloney RE, Specian V, Kelm M, Kalyanaraman B, Rodriguez J, Feelisch M. NO adducts in mammalian red blood cells: too much or too little? Nat Med. 2003; 9: 481482.[CrossRef][Medline] [Order article via Infotrieve]
13. Rassaf T, Bryan NS, Kelm M, Feelisch M. Concomitant presence of N-nitroso and S-nitroso proteins in human plasma. Free Radic Biol Med. 2002; 33: 15901596.[CrossRef][Medline] [Order article via Infotrieve]
14. Rassaf T, Feelisch M, Kelm M. Circulating NO pool: Assessment of nitrite and nitroso species in blood and tissues. Free Radic Biol Med. 2004; 36: 413422.[CrossRef][Medline] [Order article via Infotrieve]
15. Bryan NS, Fernandez BO, Bauer SM, Garcia-Saura MF, Milsom AB, Rassaf T, Maloney RE, Bharti A, Rodriguez J, Feelisch M. Nitrite is a signaling molecule and regulator of gene expression in mammalian tissues. Nat Chem Biol. 2005; 1: 290297.[CrossRef][Medline] [Order article via Infotrieve]
16. Flögel U, Decking UKM, Gödecke A, Schrader J. Contribution of NO to ischemia-reperfusion injury in the saline-perfused heart: a study in endothelial NO synthase knockout mice. J Mol Cell Cardiol. 1999; 31: 827836.[CrossRef][Medline] [Order article via Infotrieve]
17. Flögel U, Laussmann T, Gödecke A, Abanador N, Schäfer M, Fingas CD, Metzger S, Levkau B, Jacoby C, Schrader J. Lack of myoglobin causes a switch in cardiac substrate selection. Circ Res. 2005; 96: e68e75.
18. Webb A, Bond R, McLean P, Uppal R, Benjamin N, Ahluwalia A. Reduction of nitrite to nitric oxide during ischemia protects against myocardial ischemia-reperfusion damage. Proc Natl Acad Sci U S A. 2004; 101: 1368313688.
19. Zweier JL, Wang P, Samouilov A, Kuppusamy P. Enzyme-independent formation of nitric oxide in biological tissues. Nat Med. 1995; 1: 804809.[CrossRef][Medline] [Order article via Infotrieve]
20. Merx MW, Flogel U, Stumpe T, Gödecke A, Decking UK, Schrader J. Myoglobin facilitates oxygen diffusion. FASEB J. 2001; 15: 10771079.
21. Nosek TM, Fender KY, Godt RE. It is diprotonated inorganic phospate that depresses force in skinned skeletal muscle fibers. Science. 1987; 236: 191193.
22. Ross jr J. Myocardial perfusion-contraction matching. Implications for coronary heart disease and hibernation. Circulation. 1991; 83: 10761083.
23. Heusch G, Schulz R, Rahimtoola SH. Myocardial hibernation: a delicate balance. Am J Physiol Heart Circ Physiol. 2005; 288: H984H999.
24. Martin C, Schulz R, Post H, Boengler K, Kelm M, Kleinbongard P, Gres P, Skyschally A, Konietzka I, Heusch G. Microdialysis-based analysis of interstitial NO in situ: NO synthase-independent NO formation during myocardial ischemia. Cardiovasc Res. 2007; 74: 4655.
25. Tomoda A, Murakami E, Shibuya T. Changes in nitric oxide generated by the oxidation of oxymyoglobin by nitrite. Tohoku J Exp Med. 1997; 182: 6167.[Medline] [Order article via Infotrieve]
26. Reutov V, Sorokina E, Kaiushin L. The nitric oxide cycle in mammals and nitrite reducing activity of heme-containing proteins. Vopr Med Khim. 1994; 40: 3135.[Medline] [Order article via Infotrieve]
27. Shiva S, Huang Z, Grubina R, Sun J, Ringwood LA, Macarthur PH, Xu X, Murphy E, Darley-Usmar VM, Gladwin MT. Deoxymyoglobin is a nitrite reductase that generates nitric oxide and regulates mitochondrial respiration. Circ Res. 2007.
28. Duranski MR, Greer JJ, Dejam A, Jaganmohan S, Hogg N, Langston W, Patel RP, Yet SF, Wang X, Kevil CG, Gladwin MT, Lefer DJ. Cytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver. J Clin Invest. 2005; 115: 12321240.[CrossRef][Medline] [Order article via Infotrieve]
29. Richardson RS, Duteil S, Wary C, Wray DW, Hoff J, Carlier PG. Human skeletal muscle intracellular oxygenation: the impact of ambient oxygen availability. J Physiol (Lond). 2006; 571: 415424.
30. Richardson RS, Newcomer SC, Noyszewski EA. Sceletal muscle intracellular pO2 assessed by myoglobin desaturation: response to graded exercise. J Appl Physiol. 2001; 91: 26792685.
31. Vanderthommen M, Duteil S, Wary C, Raynaud JS, Leroy-Willing A, Crielaard JM, Carlier PG. A comparison of voluntary and electrically induced contractions by interleaved 1H- and 31P-NMRS in humans. J Appl Physiol. 2003; 94: 10121024.
32. Xu W, Charles IG, Moncada S. Nitric oxide: orchestrating hypoxia regulation through mitochondrial respiration and the endoplasmic reticulum stress response. Cell Res. 2005; 15: 6365.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
J. W. Calvert and D. J. Lefer Myocardial protection by nitrite Cardiovasc Res, July 15, 2009; 83(2): 195 - 203. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. G Hord, Y. Tang, and N. S Bryan Food sources of nitrates and nitrites: the physiologic context for potential health benefits Am. J. Clinical Nutrition, July 1, 2009; 90(1): 1 - 10. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R. Cossins, D. R. Williams, N. S. Foulkes, M. Berenbrink, and A. Kipar Diverse cell-specific expression of myoglobin isoforms in brain, kidney, gill and liver of the hypoxia-tolerant carp and zebrafish J. Exp. Biol., March 1, 2009; 212(5): 627 - 638. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Hazarika, M. Angelo, Y. Li, A. J. Aldrich, S. I. Odronic, Z. Yan, J. S. Stamler, and B. H. Annex Myocyte Specific Overexpression of Myoglobin Impairs Angiogenesis After Hind-Limb Ischemia Arterioscler. Thromb. Vasc. Biol., December 1, 2008; 28(12): 2144 - 2150. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Basu, N. A. Azarova, M. D. Font, S. B. King, N. Hogg, M. T. Gladwin, S. Shiva, and D. B. Kim-Shapiro Nitrite Reductase Activity of Cytochrome c J. Biol. Chem., November 21, 2008; 283(47): 32590 - 32597. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. H. McNulty, S. Scott, V. Kehoe, M. Kozak, L. I. Sinoway, and J. Li Nitrite consumption in ischemic rat heart catalyzed by distinct blood-borne and tissue factors Am J Physiol Heart Circ Physiol, November 1, 2008; 295(5): H2143 - H2148. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Webb, A. B. Milsom, K. S. Rathod, W. L. Chu, S. Qureshi, M. J. Lovell, F. M.J. Lecomte, D. Perrett, C. Raimondo, E. Khoshbin, et al. Mechanisms Underlying Erythrocyte and Endothelial Nitrite Reduction to Nitric Oxide in Hypoxia: Role for Xanthine Oxidoreductase and Endothelial Nitric Oxide Synthase Circ. Res., October 24, 2008; 103(9): 957 - 964. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. T. Gladwin and D. B. Kim-Shapiro The functional nitrite reductase activity of the heme-globins Blood, October 1, 2008; 112(7): 2636 - 2647. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. F. Alzawahra, M. A. H. Talukder, X. Liu, A. Samouilov, and J. L. Zweier Heme proteins mediate the conversion of nitrite to nitric oxide in the vascular wall Am J Physiol Heart Circ Physiol, August 1, 2008; 295(2): H499 - H508. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. C. Minneci, K. J. Deans, S. Shiva, H. Zhi, S. M. Banks, S. Kern, C. Natanson, S. B. Solomon, and M. T. Gladwin Nitrite reductase activity of hemoglobin as a systemic nitric oxide generator mechanism to detoxify plasma hemoglobin produced during hemolysis Am J Physiol Heart Circ Physiol, August 1, 2008; 295(2): H743 - H754. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. O. Lundberg and E. Weitzberg Nitrite reduction to nitric oxide in the vasculature Am J Physiol Heart Circ Physiol, August 1, 2008; 295(2): H477 - H478. [Full Text] [PDF] |
||||
![]() |
U. B. Hendgen-Cotta, M. W. Merx, S. Shiva, J. Schmitz, S. Becher, J. P. Klare, H.-J. Steinhoff, A. Goedecke, J. Schrader, M. T. Gladwin, et al. Nitrite reductase activity of myoglobin regulates respiration and cellular viability in myocardial ischemia-reperfusion injury PNAS, July 22, 2008; 105(29): 10256 - 10261. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. M. Gonzalez, S. Shiva, P. S. Vincent, L. A. Ringwood, L.-Y. Hsu, Y. Y. Hon, A. H. Aletras, R. O. Cannon III, M. T. Gladwin, and A. E. Arai Nitrite Anion Provides Potent Cytoprotective and Antiapoptotic Effects as Adjunctive Therapy to Reperfusion for Acute Myocardial Infarction Circulation, June 10, 2008; 117(23): 2986 - 2994. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. N. Vinogradov and L. Moens Diversity of Globin Function: Enzymatic, Transport, Storage, and Sensing J. Biol. Chem., April 4, 2008; 283(14): 8773 - 8777. [Full Text] [PDF] |
||||
![]() |
C. Rosenberger, M. Goldfarb, A. Shina, S. Bachmann, U. Frei, K.-U. Eckardt, T. Schrader, S. Rosen, and S. N. Heyman Evidence for sustained renal hypoxia and transient hypoxia adaptation in experimental rhabdomyolysis-induced acute kidney injury Nephrol. Dial. Transplant., April 1, 2008; 23(4): 1135 - 1143. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Grubina, S. Basu, M. Tiso, D. B. Kim-Shapiro, and M. T. Gladwin Nitrite Reductase Activity of Hemoglobin S (Sickle) Provides Insight into Contributions of Heme Redox Potential Versus Ligand Affinity J. Biol. Chem., February 8, 2008; 283(6): 3628 - 3638. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. T. Gladwin Evidence Mounts That Nitrite Contributes to Hypoxic Vasodilation in the Human Circulation Circulation, February 5, 2008; 117(5): 594 - 597. [Full Text] [PDF] |
||||
![]() |
T. S. Isbell, M. T. Gladwin, and R. P. Patel Hemoglobin oxygen fractional saturation regulates nitrite-dependent vasodilation of aortic ring bioassays Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2565 - H2572. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |